Cornea

FDA feedback backs urcosimod’s Phase 2b/3 plan for neuropathic corneal pain, defining a meaningful pain endpoint in an unmet field.

FDA authorizes compassionate use of urcosimod for neuropathic corneal pain, a condition that causes severe pain and sensitivity of the eyes, face, or head.

Post‑Pfizer mRNA shots show short‑term corneal thickening and lower endothelial cell density, prompting closer monitoring for graft or low‑count patients.

Patients underwent a full ophthalmologic examination that included optical coherence tomography (OCT), OCT angiography, and biometry.

“Remarkable” results were reportedly obtained with hypotony with hydroxypropyl methylcellulose.

An in-depth look at the FDA approvals and clinical milestones that defined 2025 and how they are poised to influence practice patterns moving into 2026.

Retina experts unpack MacTel type 2, why anti-VEGF falls short, and how new cell-based gene therapy fits real-world care.

Tips for optimizing surgical techniques to reduce recurrence and enhance outcomes.

The grading scales were compiled with the goals of achieving conciseness and the ability to provide clear drug-dose-modification recommendations compared with the previous ocular CTCAE scale.

EndoArt is an artificial cornea endothelial layer made of a sterile biocompatible material, acrylic hydrophilic. According to the company it is the first synthetic implant to treat corneal edema.

The procedure was conducted as part of the company’s ongoing phase 1 clinical trial.

Surgeons reflect on milestones that have redefined patient care—and share a glimpse of the advances that promise to shape the next era of eye health.

Host Deborah Ristvedt, DO, is joined by Marguerite B. McDonald, MD, FACS, to discuss her journey with pioneering contributions to ophthalmology, patient-centered care, leadership, and guidance for the next generation.

Veligrotug is an intravenously delivered, anti-insulin-like growth factor-1 receptor (IGF-1R) antibody for the treatment of thyroid eye disease (TED).

Clinicians discuss how the treatment compares with epi-off cross-linking, what may shape adoption, and how patient outcomes could improve.

Ophthalmologists discuss topography-guided techniques, long-term corneal health, and emerging technologies set to transform refractive surgery.

Peter J. McDonnell, MD, reflects on his early experience managing bullous keratopathy with penetrating keratoplasty and how advances like DMEK have transformed outcomes across corneal, refractive, and cataract surgery.

Chiu discusses factors affecting adoption of the FDA-approved epi-on therapy, from clinic setup to insurance coverage, while highlighting its safety and efficacy.

Rajpal shares his perspectives on the newly FDA-approved treatment, clinical benefits, and its potential impact on keratoconus management.

The trial evaluated the safety, efficacy, and tolerability of AURN001 in patients with corneal edema secondary to corneal endothelial dysfunction.

The incision-free therapeutic for keratoconus is expected to be commercially available in early 2026, according to the company.